Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers-Reference-Cited by-同舟云学术

Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers

Published:2022-03-02 Issue:7900 Volume:603 Page:335-342
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Kobayashi Yoshihisa^ORCID,Chhoeu Chhayheng,Li Jiaqi,Price Kristin S.^ORCID,Kiedrowski Lesli A.,Hutchins Jamie L.,Hardin Aaron I.^ORCID,Wei Zihan^ORCID,Hong Fangxin,Bahcall Magda,Gokhale Prafulla C.^ORCID,Jänne Pasi A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04451-4.pdf

Reference44 articles.

1. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

2. Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).

3. Hallin, J. et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020).

4. Middleton, G. et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 583, 807–812 (2020).

5. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Significance of Key Proteins in the RAS Signaling Pathway: Implications for Cancer and Therapeutic Targets;OBM Genetics;2024-05-24

2. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma;Cell Reports;2024-04

3. Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data;2024-02-23

4. Unraveling the Significance of Mg²⁺ Dependency and Nucleotide Binding Specificity of H-RAS;The Journal of Physical Chemistry B;2024-02-14

5. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma;npj Precision Oncology;2024-02-03